Preferred Drug Lists and Medicaid Prescriptions

Abdelgawad, Tamer; Egbuonu-Davis, Lisa

doi:10.2165/00019053-200624003-00005

Cited by 12 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(iii) We test the extent to which state Medicaid programs vs. patients assumed the financial responsibility of increased psychotropic medication prescriptions. While Medicaid co-payments are federally regulated to low levels (e.g., a maximum of $4 to $8 for enrollees up to 150% FPL), previous research shows that such cost-sharing can reduce medication use within Medicaid (Soumerai et al 1991;Soumerai et al 1987;Abdelgawad and Egbuonu-Davis 2006;Ridley and Axelsen 2006). 7 (iv)…”

Section: Medicaid and Mental Illnessmentioning

confidence: 99%

Public Insurance and Psychotropic Prescription Medications for Mental Illness

Maclean¹,

Cook²,

Carson³

2017

View full text Add to dashboard Cite

Mental illnesses are prevalent in the United States and globally. Cost is a critical barrier to treatment receipt. We study the effects of recent and major eligibility expansions within Medicaid, a public insurance system for the poor in the U.S., on psychotropic prescription medications for mental illness. We estimate differences-indifferences models using administrative data on medications for which Medicaid was a third-party payer over the period 2011 to 2017. Our findings suggest that these expansions increased psychotropic prescriptions by 22.3%. We show that Medicaid, and not patients, financed these prescriptions. For states expanding Medicaid, the total cost of these prescriptions was $30.8M. Expansion effects were experienced across most major mental illness categories and across states with different levels of patient need, system capacity, and expansion scope. We find no evidence that Medicaid expansion reduced a proxy for serious mental illness: suicide.

show abstract

Section: Medicaid and Mental Illnessmentioning

confidence: 99%

Public Insurance and Psychotropic Prescription Medications for Mental Illness

Maclean¹,

Cook²,

Carson³

2017

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10] Research has shown that prior authorization requirements for NSAIDs and, specifically, COX-2 inhibitors have been successful in reducing NSAID use. [7][8][9][10] Research has shown that prior authorization requirements for NSAIDs and, specifically, COX-2 inhibitors have been successful in reducing NSAID use.…”

Section: Medicaid Prescription Formulary Restrictions and Arthritis Tmentioning

confidence: 99%

Medicaid Prescription Formulary Restrictions and Arthritis Treatment Costs

Johnson

Stahl-Moncada

2008

Am J Public Health

View full text Add to dashboard Cite

show abstract

“…Two studies found that Medicaid beneficiaries taking a restricted statin medication filled fewer prescriptions and were more likely to be nonadherent than unrestricted patients. 53,54 A concern is also raised regarding the fact that low-income beneficiaries will be disproportionately affected in their responses to cost sharing. 29 For from the clinical, patient, and provider perspectives were studied less often (45%, 42%, and 12% of the studies, respectively).…”

mentioning

confidence: 99%